In this study, the new GLP-1 receptor agonist lixisenatide significantly improved glycaemic control from a mildly elevated mean baseline HbA1c [∼7.55% (∼59.0 mmol/mol)] in patients with Type 2 diabetes mellitus inadequately controlled with metformin. This evidence concerns the gene GLP1R and diabetes mellitus.